2 Top Biotech Stocks to Buy Right Now

Investors can't discount the possibility that the field of cellular medicine is a little overhyped right now, but the potential is huge.

Researchers are toiling away at the bench and in the clinic to determine the best cell types to use as a starting point for a therapy, the best ways to engineer them, and the best time and dosing regimen for administering them to patients. It'll take time to figure all of that out, and some approaches (and companies) will prove to be a dead end, but cellular medicines promise to drive a step change in health outcomes. 

Two companies with unique and promising approaches are Fate Therapeutics (NASDAQ: FATE) and Iovance Biotherapeutics (NASDAQ: IOVA). The former is developing a pipeline leaning heavily on natural killer (NK) cells, while the latter has collected promising results for tumor infiltrating lymphocytes (TILs). After recent data updates, investors might consider them two of the top biotech stocks to buy right now.

Continue reading

Source Fool.com